Recommended Starting Dose of Hydrocodone for Acute Pain
For opioid-naïve adults with acute pain, start with hydrocodone 5 mg (combined with acetaminophen 325 mg) every 4-6 hours as needed, with a maximum of 20-30 MME per day. 1, 2
Dosing Algorithm
Initial Prescription
- Start low: Hydrocodone 5 mg/acetaminophen 325 mg, 1-2 tablets every 4-6 hours as needed
- Daily maximum: Do not exceed 8 tablets of the 5 mg/325 mg formulation (40 mg hydrocodone = 40 MME/day) 2
- Duration: Prescribe for 3 days or less; rarely should exceed 7 days 3
Dose Selection Based on Pain Severity
The 2022 CDC guidelines explicitly state that the lowest starting dose for opioid-naïve patients is often equivalent to 5-10 MME per single dose or 20-30 MME/day total 1. Since hydrocodone has a 1.0 conversion factor (1 mg hydrocodone = 1 MME), this translates to:
- Mild-moderate pain: 5 mg hydrocodone every 4-6 hours (20-30 mg/day = 20-30 MME/day)
- Moderate-severe pain: 10 mg hydrocodone every 4-6 hours (maximum 60 mg/day = 60 MME/day), but this exceeds the recommended starting range and should be reserved for exceptional circumstances
Critical Thresholds to Remember
- 20-30 MME/day: Recommended starting range for opioid-naïve patients 1
- 50 MME/day: Pause and reassess before crossing this threshold; requires careful justification 1
- 90 MME/day: Avoid or carefully justify; associated with significantly increased overdose risk 3
Formulation-Specific Dosing from FDA Label
The FDA-approved dosing provides three formulation options 2:
- 5 mg/325 mg: 1-2 tablets every 4-6 hours (maximum 8 tablets/day = 40 MME/day)
- 7.5 mg/325 mg: 1 tablet every 4-6 hours (maximum 6 tablets/day = 45 MME/day)
- 10 mg/325 mg: 1 tablet every 4-6 hours (maximum 6 tablets/day = 60 MME/day)
For opioid-naïve patients, the 5 mg/325 mg formulation is the appropriate starting point, as it allows titration within the recommended 20-30 MME/day range.
Evidence Supporting Lower Doses
Research demonstrates that 5 mg hydrocodone provides effective analgesia for acute musculoskeletal pain 4, 5. A 2005 randomized controlled trial showed that 5 mg hydrocodone with acetaminophen produced significant pain relief at 30 and 60 minutes in ED patients with fractures 5. However, a 2024 systematic review found that oral opioids provide only small benefits (mean difference -8.8 points on 0-100 scale) for acute musculoskeletal pain in adults, with high certainty evidence 6.
Critical Safety Considerations
Monitor Closely in First 24-72 Hours
The FDA label emphasizes following patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy 2. This is when overdose risk is highest.
Avoid Common Prescribing Pitfalls
- Do not prescribe "just in case": Only prescribe the quantity needed for expected pain duration 3
- Do not start with higher-strength formulations: The 7.5 mg and 10 mg tablets are not appropriate initial doses for opioid-naïve patients
- Do not exceed 50 MME/day without reassessment: This threshold requires careful benefit-risk evaluation 1
- Consider acetaminophen limits: Maximum 4000 mg acetaminophen per day (some recommend 3000 mg for chronic use)
Risk of Progression to Long-Term Use
A 2022 Veterans Affairs study found that even brief opioid prescriptions for acute pain carry risk: patients receiving immediate, low-dose, brief supply had 3.33 times higher risk of progressing to long-term opioid use compared to those who received no opioids (absolute risk 1.1% vs 0.3%) 7. This underscores the importance of prescribing the minimum effective dose for the shortest duration.
Practical Implementation
Start with: Hydrocodone 5 mg/acetaminophen 325 mg, dispense 6-12 tablets (enough for 3 days at 1-2 tablets every 6 hours)
Reassess at 3 days: If pain persists beyond expected duration, reevaluate the diagnosis and treatment plan rather than automatically refilling 3
Alternative for severe pain: If 5 mg is clearly insufficient based on pain severity, consider 7.5 mg formulation, but this still exceeds the ideal 20-30 MME/day starting range when dosed regularly
The evidence strongly supports conservative initial dosing to minimize both immediate risks (respiratory depression, overdose) and long-term risks (progression to chronic opioid use, opioid use disorder).